Physician profile
Olga Maimon
NPI 1073598850
$9,483.15
in general payments reported to CMS, 2019-2025
37 companies · $2,557 in 2025
The $2,557 reported for 2025 was more than what 84% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $682 · 2020: $347 · 2021: $927 · 2022: $981 · 2023: $1,094 · 2024: $2,896 · 2025: $2,557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,518 · Education: $28.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,518.28 |
| Education | $28.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,288.57 | 2019-2025 | |
| Madrigal Pharmaceuticals | $1,545.09 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $835.29 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $389.35 | 2022-2025 | Tremfya, Stelara |
| Qol Medical, LLC | $318.10 | 2021-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $258.12 | 2019-2024 | Xifaxan, Trulance, Plenvu |
| Daiichi Sankyo INC. | $245.17 | 2019-2022 | |
| Pfizer INC. | $220.60 | 2023-2025 | |
| Nestle Healthcare Nutrition INC. | $198.55 | 2020-2023 | |
| Allergan, INC. | $182.58 | 2019-2020 | |
| Gilead Sciences, INC. | $146.47 | 2019-2023 | |
| Celgene Corporation | $121.73 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $91.88 | 2019-2025 | |
| Novo Nordisk INC | $81.98 | 2019-2024 | Wegovy |
| Merck Sharp & Dohme LLC | $66.91 | 2020-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $54.55 | 2019-2024 | Entyvio |
| Redhill Biopharma INC. | $39.76 | 2020-2021 | |
| Laborie Medical Technologies Corp. | $35.61 | 2023 | |
| Organon LLC | $33.54 | 2024-2025 | Hadlima |
| Ferring Pharmaceuticals INC. | $29.22 | 2020-2023 | Rebyota |
| Ucb, INC. | $27.88 | 2019 | |
| Glaxosmithkline, LLC. | $27.60 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.57 | 2022 | |
| Amarin Pharma, INC. | $26.19 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $22.76 | 2025 | Iqirvo |
| Cumberland Pharmaceuticals, INC. | $18.84 | 2023 | Kristalose |
| Abbott Laboratories | $15.87 | 2021 | |
| Ardelyx, INC. | $15.64 | 2024 | Ibsrela |
| Aimmune Therapeutics, INC. | $15.13 | 2024 | |
| Vivus LLC | $15.00 | 2021 | |
| Braintree Laboratories, INC. | $14.36 | 2023 | Sutab |
| Indivior INC. | $13.25 | 2019 | |
| Ironwood Pharmaceuticals, INC | $13.23 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $13.07 | 2019 | |
| Romark Laboratories, Lc | $12.84 | 2020 | |
| Alfasigma USA, INC. | $11.37 | 2020 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olga Maimon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.